Video content above is prompted by the following:
- (PINKERTON) What is the role of neurokinin in the pathophysiology of vasomotor symptoms?
- (SMITH) Fezolinetant is a nonhormonal novel agent now available for the treatment of moderate to severe VMS due to menopause. How is moderate to severe VMS defined? What is the mechanism of action of fezolinetant?
- (PINKERTON) Elinzanetant is another nonhormonal, novel agent recently submitted for FDA approval for the treatment of moderate to severe VMS. What is the mechanism of action of elinzanetant, and how might the unique mechanism of NK1 antagonism help to treat other menopause-related conditions, such as mood disturbances or sleep disorders?
- (FIFFICK) What are the advantages of targeting the neurokinin pathways in menopause treatment compared with traditional hormonal approaches?
